RxDoctor Payments Data

Kyle Trauth, MD

Family Medicine · Morrilton, ARNPI 1922268911

Payments from drug & device makers

$698in general payments, 2019–2025

Across 37 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$143
  • AbbVie$141
  • Novo Nordisk$87
  • Bayer$57
  • GSK$54
  • Amgen$47
  • plus $170 from 8 others

What the payments were for

  • Food & beverage$698100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$698 in reported general payments places this provider in the 50th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$11,325
Medicare patients
147
Services billed
508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide116$130,293
TrulicityDulaglutide101$129,389
Cosentyx SyringeSecukinumab12$86,527
MounjaroTirzepatide37$42,346
EliquisApixaban70$40,428
XareltoRivaroxaban86$35,649
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$32,471
FarxigaDapagliflozin Propanediol39$31,052
Tresiba Flextouch U-200Insulin Degludec31$23,260
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$22,462
LinzessLinaclotide15$20,482
JardianceEmpagliflozin11$20,324
Spiriva RespimatTiotropium Bromide22$15,633
Bevespi AerosphereGlycopyrrolate/Formoterol Fum32$14,587
MyrbetriqMirabegron32$12,822

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$87$130,293116 claims
PfizerEliquis$33$40,42870 claims
Boehringer IngelheimJardiance, Spiriva Respimat$40$35,95733 claims
Johnson & JohnsonXarelto$11$35,64986 claims
GSKTrelegy Ellipta$54$32,47131 claims
AbbVieLinzess$141$20,48215 claims
BayerKerendia$57$10,10915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Morrilton

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →